EverFortune.AI

Taichung City, Taiwan  All Taiwan companies → — Founded 2018
Clinical AI Platform Imaging AI Specialist Specialty-Focused AI
Pre-IPO / Public (listed on Taipei Exchange)

Products

EFAI ChestSuite XR Pleural Effusion Assessment System
EverFortune.AI
Radiology & Imaging AI
The EFAI ChestSuite XR Pleural Effusion Assessment System is an AI-powered radiological computer-assisted triage and notification software that analyzes PA chest X-rays to identify and flag suspected pleural effusion, aiding in workflow prioritization.

See all 1 product →

About EverFortune.AI

EverFortune.AI is a Taiwan-based healthcare AI company that develops medical AI, cloud biomedical platforms, and medical big data products to enhance clinical workflows. Their technology focuses on AI-enabled medical software for image viewing and analysis, workflow management, remote access, reporting, and clinical notification. The company’s product catalog includes systems for various medical specialties such as radiology, cardiology, oncology, and ECG analysis.

For physicians, EverFortune.AI’s solutions aim to streamline diagnostic processes and improve patient outcomes by providing AI-assisted interpretation systems. For example, their chest X-ray interpretation system helps detect major findings and abnormalities, reducing subjectivity and increasing workflow efficiency. They also offer systems for acute aortic syndrome detection, which prioritizes high-risk cases, and radiotherapy organ segmentation to enhance precision in cancer treatment. The company’s EFAI ERSUITE CT Appendicitis Assessment System (APPEN-CT-100) received FDA 510(k) clearance in April 2026 as radiological computer-assisted triage and notification software, functioning as a clinical co-pilot to optimize triage workflows.

EverFortune.AI emphasizes that their AI systems are designed to assist medical professionals, not replace their diagnoses, by providing objective information and reducing time spent on administrative tasks. This allows physicians to dedicate more time to patient communication and delivering higher quality care. The company has secured numerous medical device approvals globally, including from the US FDA and Taiwan’s TFDA, demonstrating their commitment to international standards and clinical deployment.

Focus Areas

AI-driven diagnostic solutions cloud biomedical platforms medical big data oncology neurology cardiology radiology precision medicine digital healthcare

Business Intelligence

TechnologyAI-enabled medical software for image viewing and analysis, workflow management, remote access, reporting, and clinical notification workflows. Utilizes deep learning algorithms, natural language processing (NLP), convolutional neural networks (CNN), and recurrent neural networks (RNN).

What Physicians Need to Know

AI-driven Diagnostic Solutions
EverFortune.AI specializes in AI-powered software for image viewing and analysis, workflow management, remote access, reporting, and clinical notification workflows across various medical specialties. Their solutions include systems for chest X-ray interpretation, acute aortic syndrome detection, radiotherapy organ segmentation, bone scintigraphy computer-assisted detection, intracerebral hemorrhage detection, myocardial perfusion reporting, bone age assessment, and STEMI detection.
Cloud Biomedical Platforms & Medical Big Data
The company develops cloud biomedical platforms and leverages medical big data to create AI applications relevant to clinical needs. They have access to a large medical database from China Medical University Hospital, which aids in the development of their AI solutions.
Oncology
EverFortune.AI offers AI-assisted solutions for cancer radiotherapy, supporting the full workflow from organ contouring to adaptive treatment evaluation. Their 'EFAI RT Suite CT HCAP-Segmentation System' automatically delineates organs-at-risk on CT images for radiation therapy planning. They also assist in analyzing patient recovery data to predict recurrence or side effects.
Neurology
In neurology, EverFortune.AI provides the 'EFAI NeuroSuite CT ICH Assessment System' which analyzes non-contrast head CT scans to detect acute intracranial hemorrhage and quantify midline shift, helping prioritize urgent cases.
Cardiology
Their cardiology solutions include the 'EFAI CARDIOSUITE CTA Acute Aortic Syndrome Assessment System' for detecting signs of acute aortic syndrome on CT angiography scans, and systems for ECG analysis and myocardial perfusion reporting.
Radiology
EverFortune.AI has a strong focus on radiology, with FDA-cleared products like the 'EFAI NeuroSuite CT ICH Assessment System' for brain hemorrhage detection, 'EFAI CARDIOSUITE CTA Acute Aortic Syndrome Assessment System' for aortic conditions, and 'EFAI Bonesuite XR Bone Age Pro Assessment System' for pediatric bone age assessment. Their 'EFAI ChestSuite XR Pleural Effusion Assessment System' assists in identifying pleural effusion on chest X-rays.
Precision Medicine & Digital Healthcare
The company is committed to advancing precision medicine and digital healthcare through AI, aiming to provide solutions to experts anytime, anywhere. They integrate multidimensional data for systems like their Pediatric Growth Assessment System.
Physician Tip

EverFortune.AI's solutions are designed to enhance medical workflow and boost patient outcomes by providing AI-powered assistance for diagnosis, treatment planning, and case prioritization. Physicians can leverage their systems to accelerate image review, reduce the risk of missed diagnoses, and streamline administrative tasks, allowing more time for patient communication and complex clinical decisions. The AI tools offer standardized, guideline-adherent outputs and integrate with existing PACS and TPS workflows, aiming for seamless clinical deployment.

EverFortune.AI's systems are designed for seamless integration into existing clinical environments. For radiotherapy, their AutoSeg system connects directly to major Treatment Planning Systems (TPS) like Eclipse, RayStation, Monaco, and Pinnacle via DICOM. Their bone age interpretation software can be customized to integrate with existing PACS systems in hospitals. They also provide notifications through PACS/workstations to help prioritize and triage cases.

Products by EverFortune.AI

1 product in the directory

EFAI ChestSuite XR Pleural Effusion Assessment System
EverFortune.AI
Radiology & Imaging AI
The EFAI ChestSuite XR Pleural Effusion Assessment System is an AI-powered radiological computer-assisted triage and notification software that analyzes PA chest X-rays to identify and flag suspected pleural effusion, aiding in workflow prioritization.

What the Web Says

EverFortune.AI appears to be a company with a mixed and largely negative online presence. While they have announced products in the healthcare AI space, including a care robot and a CT Midline Shift Assessment System, many online discussions, particularly on Reddit, suggest that some ventures associated with the name or similar names might be scams. There is limited information on traditional review sites like G2, Glassdoor, or Capterra directly for "EverFortune.AI" as a product or employer.

Overall: Negative

Strengths

  • Development of AI-powered healthcare solutions, such as a care robot and a CT Midline Shift Assessment System.
  • FDA substantial equivalence for a medical device.

Limitations

  • Multiple Reddit discussions raise concerns about potential scam activities associated with similar company names or business models, including issues with cashing out earnings, new websites, and misleading payment promises.
  • Lack of verifiable product or employer reviews on major platforms like G2, Glassdoor, or Capterra.
  • Some users reported being scammed out of money.
  • Difficulty in distinguishing legitimate operations from potential scams due to similar naming conventions in the AI space.

Based on reviews from: Reddit, Google Search (various news articles and official announcements), FDA

Last updated: 2026-10-23

Videos

News, demos, and interviews about EverFortune.AI.

Loading videos...

Videos load interactively. If none appear, search YouTube for EverFortune.AI →

View all on YouTube

Press & Coverage

Healthcare+ B2B
Ever Fortune.AI Partners with Hospitals to Build an AI-Driven Radiotherapy Platform, Targeting AI Healthcare Opportunities
On December 6, 2024, Ever Fortune.AI announced a partnership with Varian, China Medical University, Kaohsiung Veterans General Hospital, and Tungs' Taichung MetroHarbor Hospital to develop an AI Adaptive Radiotherapy Platform. This platform aims to enhance precision and minimize side effects during radiotherapy by leveraging real-time data analysis.
2024-12
Healthcare+ B2B
Ever Fortune.AI medical software nets one more approval for the US market
On September 26, 2025, Ever Fortune.AI announced that its “EFAI RT Suite CT HCAP-Segmentation System” received FDA approval, marking its 7th U.S. FDA clearance. This software uses a closed-loop AI algorithm to automatically delineate 17 types of head-and-neck organs-at-risk on CT images, streamlining radiotherapy workflows.
2025-09
Healthcare+ B2B
EverFortune.AI receives market approvals of three products in Vietnam
On October 5, 2023, Ever Fortune.AI announced that Vietnam's Ministry of Health approved three of its products for marketing: "Intelligent Cardiothoracic Ratio (iCTR) Assessment System," "Pneumothorax Detection System," and "Pleural Effusion Detection System." The company also secured a patent in Japan for its "Risk Assessment for Genetic Testing."
2023-10
Healthcare+ B2B
Ever Fortune. AI Expands Dual US-Taiwan Footprint with Appendicitis AI Approval, Accumulating 57 Global Permits
On August 18, 2026, Ever Fortune.AI announced that its AI-driven detection tool, the EFAI ERSUITE CT APPENDICITIS ASSESSMENT SYSTEM, received medical device clearance from the Taiwan FDA (TFDA), following its US FDA 510(k) clearance in April 2026. This brings the company's total global medical device certifications to 57.
2026-08
Healthcare+ B2B
Everfortune AI Expects Revenue Growth Acceleration in H2 2026, Targets Doubled Shipments for ABO Robot in 2027
Everfortune AI anticipates increased operational momentum in the second half of 2026, with revenue growth driven by the release of deferred hospital procurement projects. The company aims to double shipments of its ABO robot to 200 units in 2027 and is developing a next-generation ABO model.
2026-08
Institute for Biotechnology and Medicine Industry (IBMI)
EverFortune.AI Secures World's First FDA PCCP Approval for Radiotherapy AI "Seg Pro V3"
On May 25, 2026, EverFortune.AI announced that its AI-powered medical software, the Radiotherapy Organ Auto-Contouring System (Seg Pro V3), received US FDA 510(k) clearance. This marks the first global approval in its category under the FDA's Predetermined Change Control Plans (PCCP), allowing for controlled model updates.
2026-05
BigGo Finance
Ever Fortune.AI (6841.TW) Announces Capital Increase Record Date for Employee Stock Option Conversion
On February 1, 2026, Ever Fortune.AI announced a capital increase resulting from the exercise of employee stock options. The company will issue 25,000 new common shares, raising NT$250,000 (approximately USD 7,900).
2026-02
Taiwan News
TAIEX ends week down 1,069 points
On October 23, 2026, medical information technology and AI-assisted diagnostic stocks, including Ever Fortune.AI, showed relative resilience in the TAIEX. Ever Fortune.AI edged down 0.55% on a day where the overall market saw a significant decline.
2026-10

Frequently Asked Questions

EverFortune.AI provides AI-assisted solutions across various specialties. In oncology, they offer AI-assisted radiotherapy workflow solutions like AutoSeg for automated organ contouring and AdaptInsight for adaptive treatment evaluation. For radiology, they have AI-assisted interpretation systems for spine fractures and chest X-rays, detecting abnormalities like lung conditions, cardiomegaly, and fractures. Their solutions also extend to cardiology with products like "EFAI Cardiosuite SPECT Myocardial Perfusion Agile Workflows" for analyzing myocardial perfusion images. They also have products greenlighted for cardiovascular and brain neurology.
EverFortune.AI prioritizes regulatory compliance, holding numerous medical device certifications. They have secured 41 medical device certifications, including 15 from Taiwan's TFDA and 11 from the U.S. FDA, covering various applications. Their products, such as the automated organ-at-risk contouring system for radiation therapy, have received US FDA clearance and TFDA approval. They build their cloud medical platforms with strict and stable cybersecurity regulations, collaborating with international cloud providers to meet information security standards.
EverFortune.AI offers cloud biomedical platforms designed for efficiency, flexibility, and scalability, with modular application designs that can be customized to client needs. These platforms aim to enhance service value and optimize operational processes for healthcare institutions. They also provide medical big data solutions that include population and disease analysis, disease trend monitoring, and data insights to assist pharmaceutical companies and healthcare providers.
EverFortune.AI is committed to innovation in precision medicine and digital healthcare, aiming to be a leader in the field. They develop technology to enhance medical workflows and patient outcomes across various specialties. Specific products include an AI Adaptive Radiotherapy Platform that leverages real-time data analysis to adjust treatment plans for personalized cancer treatment. They also offer a Pediatric Growth Assessment System that integrates multidimensional data to monitor children's growth and identify developmental conditions early.
EverFortune.AI has demonstrated robust operational growth, with significant year-on-year revenue increases. They have secured numerous medical device certifications globally, indicating a strong market presence and regulatory acceptance. The company actively forms partnerships, including collaborations with hospitals like China Medical University, Kaohsiung Veterans General Hospital, and Tungs' Taichung MetroHarbor Hospital to develop advanced platforms. They also partner with international corporations and institutions to expand their professional medical services globally.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.